XOMA acquisition ends Generation Bio (GBIO) CEO stock and options at $4.2913 plus CVRs
Rhea-AI Filing Summary
Generation Bio Co. insider Yalonda Howze, interim CEO and President, reported the end of her equity position following the company’s acquisition by XOMA Royalty Corporation. On February 9, 2026, her remaining 3,759 shares of common stock were exchanged under the merger terms, leaving zero shares beneficially owned.
Under the merger agreement, each tendered share of Generation Bio common stock was exchanged for $4.2913 in cash per share plus one contingent value right (CVR) per share, with an estimated maximum contingent cash consideration of $25.01 per CVR. After the tender offer, XOMA’s merger subsidiary was combined with Generation Bio, which continued as a wholly owned subsidiary of XOMA.
Immediately before the merger became effective, each outstanding, unexercised stock option with an exercise price per share equal to or above the $4.2913 cash amount was automatically cancelled for no consideration. In this filing, Howze reports the disposition and resulting cancellation of multiple stock option grants, each going from thousands of options outstanding to zero following the transaction.
Positive
- None.
Negative
- None.
Insights
Merger with XOMA cashes out common shares and cancels out-of-the-money options.
The disclosure shows XOMA Royalty Corporation completed its acquisition of Generation Bio. Each tendered share received $4.2913 in cash plus one CVR with an estimated maximum additional consideration of $25.01. After the tender offer, Generation Bio became a wholly owned subsidiary of XOMA.
For interim CEO Yalonda Howze, all reported equity interests were effectively eliminated at closing. She exchanged 3,759 common shares into the merger consideration and now reports zero shares beneficially owned. Several stock option grants, all with exercise prices at or above $4.2913, were automatically cancelled for no consideration under the merger agreement.
From an investor perspective, this confirms key economic terms of the buyout: a fixed cash payment per share, plus CVRs that could pay up to $25.01 per right if specified conditions are met. It also clarifies that underwater options did not participate in the consideration, which simplifies the post-transaction capital structure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 10,710 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 11,883 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 25,102 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 7,630 | $0.00 | -- |
| U | Common Stock | 3,759 | $0.00 | -- |
Footnotes (1)
- Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
